1
|
van Winkel CA, Fan X, Giesen D, Gauderat G, Pattarini L, Jaquin T, Barakat A, Bigne AMDL, Richter M, Andersen N, Legrand J, Lelièvre H, de Vries EG, Morales-Kastresana A, de Hooge MNL. Abstract 3579: Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-3579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: PRS-344/S095012 is a novel 4-1BB (CD137) and programmed death-ligand 1 (PD-L1) bispecific antibody-Anticalin® fusion protein (MabcalinTM protein) designed to cluster 4-1BB on activated T cells exclusively in the presence of PD-L1 expressing cells. We aimed to study PRS-344/S095012 in vivo biodistribution and pharmacokinetics with 89Zr-positron emission tomography (PET) at a dose with antitumoral activity in mice and evaluate the contribution of each targeting arm.
Methods: PRS-344/S095012 lacks cross-reactivity to murine 4-1BB and PD-L1. To explore the PRS-344/S095012 biodistribution in a humanized 4-1BB knock-in mouse model, we synthesized the surrogate 89Zr-Atezo-J10 with the same 4-1BB building block and cross-reactivity to murine PD-L1. Humanized 4-1BB knock-in C57BL/6J (h4-1BB KI B6) and C57BL/6J (B6) mice (n=4-6 per group) were subcutaneously engrafted with murine wildtype MC38 colon adenocarcinoma cells. Tumors were grown to a minimum of ≥50 mm3 (average 163 mm3) before tracer injection. Mice received intravenously 30 µg (2.5 MBq) of 89Zr-PRS-344/S095012 or 89Zr-Atezo-J10 supplemented with PRS-344/S095012 or Atezo-J10 up to 10 mg/kg. Four mice groups were formed to distinguish between bispecific (Atezo-J10 in h4-1BB KI B6), monospecific PD-L1 (Atezo-J10 in B6), monospecific 4-1BB (PRS-344/S095012 in h4-1BB KI B6), and isotype (PRS-344/S095012 in B6) binding up to 4 days post-injection (pi). In addition, a fifth group (5 MBq 89Zr-Atezo-J10) was studied to visualize the bispecific biodistribution up to 7 days pi. At days 1, 2, 4, or 2, 4, 7 pi, mice underwent serial PET imaging to obtain mean and maximum standardized uptake (SUVmean/max) and retro-orbital blood sampling, followed by ex vivo biodistribution.
Results: PET imaging showed 89Zr-Atezo-J10 specific tumor accumulation with higher tumor-to-blood ratios of respectively 2.2-, 2.6-, and 2.4-fold (p<0.01) at 4 days pi compared to monospecific binding of PD-L1, 4-1BB, and isotype. The ex vivo biodistribution demonstrated the same trend with respectively 4.2-, 5.5-, and 6.8-fold (p<0.01) increase in tumor-to-blood uptake for 89Zr-Atezo-J10 versus monospecific binding of PD-L1, 4-1BB, and isotype
89Zr-Atezo-J10 spleen uptake was comparable (ns) with monospecific binding of PD-L1 but elevated (p<0.01) compared to 4-1BB or isotype distribution. The uptake in lymph nodes (axillary, cervical, tumor-draining, and mesenteric) did not differ between the groups.
Conclusion: 89Zr-Atezo-J10 specific accumulation in PD-L1 expressing tumors is due to both PD-L1 and 4-1BB binding and is higher than with PD-L1 and 4-1BB mono-targeting. This preclinical study supports the clinical evaluation of 89Zr-PRS-344/S095012’s whole-body distribution and the development of tumor-specific 4-1BB targeting bispecifics.
Citation Format: Claudia A. van Winkel, Xiaoyu Fan, Danique Giesen, Glenn Gauderat, Lucia Pattarini, Thomas Jaquin, Anissa Barakat, Anne-Marie De La Bigne, Marleen Richter, Nicole Andersen, Julie Legrand, Helene Lelièvre, Elisabeth G. de Vries, Aizea Morales-Kastresana, Marjolijn N. Lub- de Hooge. Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3579.
Collapse
Affiliation(s)
| | - Xiaoyu Fan
- 1University Medical Center Groningen, Groningen, Netherlands
| | - Danique Giesen
- 1University Medical Center Groningen, Groningen, Netherlands
| | - Glenn Gauderat
- 2Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France
| | | | | | - Anissa Barakat
- 2Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France
| | | | | | | | - Julie Legrand
- 2Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France
| | - Helene Lelièvre
- 2Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France
| | | | | | | |
Collapse
|
2
|
Meyer C, Dierick I, Gauderat G, Langenhorst J, Sarr C, Leroux E, Chenel M, Fouliard S, Passier P. How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example. Clin Pharmacol Ther 2023; 113:310-320. [PMID: 35355254 PMCID: PMC10083980 DOI: 10.1002/cpt.2596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 02/19/2022] [Indexed: 01/27/2023]
Abstract
During development of a drug, the requirement of evaluating the proarrhythmic risk and delayed repolarization needs to be fulfilled. Would it be possible to create an alternative to a thorough QT (TQT) study or is there a need to perform a dedicated TQT study? How is an alternative approach generated, what information is available, and which instructions are considered missing today to generate such an approach? This tutorial describes the considerations and path followed to create an early and feasible alternative to a TQT study using experience-based insights from a successful application to the US Food and Drug Administration for GLPG1972, an ADAMTS-5 inhibitor, and discusses the approach used in light of the current guidelines and literature.
Collapse
Affiliation(s)
| | | | - Glenn Gauderat
- Translational Medicine Division, Servier, Suresnes, France
| | | | | | - Emilie Leroux
- Translational Medicine Division, Servier, Suresnes, France
| | | | | | | |
Collapse
|
3
|
Tosca EM, Gauderat G, Fouliard S, Burbridge M, Chenel M, Magni P. Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach. CPT Pharmacometrics Syst Pharmacol 2021; 10:1396-1411. [PMID: 34708556 PMCID: PMC8592518 DOI: 10.1002/psp4.12710] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 08/02/2021] [Accepted: 08/17/2021] [Indexed: 12/19/2022]
Abstract
MET receptor tyrosine kinase inhibitors (TKIs) can restore sensitivity to gefitinib, a TKI targeting epidermal growth factor receptor (EGFR), and promote apoptosis in non-small cell lung cancer (NSCLC) models resistant to gefitinib treatment in vitro and in vivo. Several novel MET inhibitors are currently under study in different phases of development. In this work, a novel tumor-in-host modeling approach, based on the Dynamic Energy Budget (DEB) theory, was proposed and successfully applied to the context of poly-targeted combination therapies. The population DEB-based tumor growth inhibition (TGI) model well-described the effect of gefitinib and of two MET inhibitors, capmatinib and S49076, on both tumor growth and host body weight when administered alone or in combination in an NSCLC mice model involving the gefitinib-resistant tumor line HCC827ER1. The introduction of a synergistic effect in the combination DEB-TGI model allowed to capture gefitinib anticancer activity enhanced by the co-administered MET inhibitor, providing also a quantitative evaluation of the synergistic drug interaction. The model-based comparison of the two MET inhibitors highlighted that S49076 exhibited a greater anticancer effect as well as a greater ability in restoring sensitivity to gefitinib than the competitor capmatinib. In summary, the DEB-based tumor-in-host framework proposed here can be applied to routine combination xenograft experiments, providing an assessment of drug interactions and contributing to rank investigated compounds and to select the optimal combinations, based on both tumor and host body weight dynamics. Thus, the combination tumor-in-host DEB-TGI model can be considered a useful tool in the preclinical development and a significant advance toward better characterization of combination therapies.
Collapse
Affiliation(s)
- Elena M. Tosca
- Laboratory of Bioinformatics, Mathematical Modelling and Synthetic BiologyDepartment of ElectricalComputer and Biomedical EngineeringUniversità degli Studi di PaviaPaviaItaly
| | - Glenn Gauderat
- Clinical Pharmacokinetics and Pharmacometrics DivisionServierSuresnesFrance
| | - Sylvain Fouliard
- Clinical Pharmacokinetics and Pharmacometrics DivisionServierSuresnesFrance
| | - Mike Burbridge
- Center for Therapeutic Innovation in OncologyServierSuresnesFrance
- Present address:
Engitix therapeuticsLondonUK
| | - Marylore Chenel
- Clinical Pharmacokinetics and Pharmacometrics DivisionServierSuresnesFrance
- Present address:
Pharmetheus ABUppsalaSweden
| | - Paolo Magni
- Laboratory of Bioinformatics, Mathematical Modelling and Synthetic BiologyDepartment of ElectricalComputer and Biomedical EngineeringUniversità degli Studi di PaviaPaviaItaly
| |
Collapse
|
4
|
Gély CA, Huesca A, Picard-Hagen N, Toutain PL, Berrebi A, Gauderat G, Gayrard V, Lacroix MZ. A new LC/MS method for specific determination of human systemic exposure to bisphenol A, F and S through their metabolites: Application to cord blood samples. Environ Int 2021; 151:106429. [PMID: 33636497 DOI: 10.1016/j.envint.2021.106429] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 01/20/2021] [Accepted: 01/27/2021] [Indexed: 06/12/2023]
Abstract
Due to restriction of the use of BPA, several structural analogues such as BPS and BPF have been proposed for its replacement in many consumer products. This has increased the prevalence of BPS and BPF in urine from tested cohorts. However, these substitutes have similar endocrine disrupting properties to BPA, particularly on reproductive and metabolic functions, which suggests that fetal exposure to these analogues could be of concern for human health. Bisphenols (BPs) are mainly metabolized to glucuronides (BP-Gs), which are considered as inactive but provide a relevant marker of fetal exposure during pregnancy. In most instances, these metabolites are indirectly quantified after hydrolysis and measurement of the corresponding native BPs, which may lead to bias due to spurious BPs contamination during blood collection and/or analyses. We have developed a new method for direct quantification of BP-Gs, which has the advantage of not being affected by errors related to the presence of BPs. First, BP-Gs were extracted from plasma by anion exchange solid phase extraction. They were then labelled with dansyl chloride, using experimentally-optimized incubation conditions, after which the dansyl derivatives were injected into an on-line SPE-UHPLC/MS/MS system. The performance of the method, in terms of sensitivity, precision and accuracy, was evaluated in plasma over a concentration range of 0.05-5 ng/mL. The intra- and inter-day CV% precision were lower than 20% with accuracies ranging from 93% to 115%. The limit of quantification was set at 0.05 ng/mL. The method was then applied to measure BP-Gs in forty-four cord plasma samples. Although no BPF-G was found, BPA-G and BPS-G was determined in almost half of the cord plasma samples with concentration ranges nd-0.089 ng/mL and nd-0.586 ng/mL, respectively.
Collapse
Affiliation(s)
- C A Gély
- INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France; ToxAlim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse, France.
| | - A Huesca
- INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France.
| | - N Picard-Hagen
- ToxAlim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse, France.
| | - P L Toutain
- The Royal Veterinary College, University of London, London, United Kingdom.
| | - A Berrebi
- Hôpital Paule de Viguier, Service de Gynécologie Obstétrique, CHU Toulouse, F-31059 Toulouse, France.
| | - G Gauderat
- ToxAlim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse, France.
| | - V Gayrard
- ToxAlim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse, France.
| | - M Z Lacroix
- INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France.
| |
Collapse
|
5
|
Grandin FC, Lacroix MZ, Gayrard V, Gauderat G, Mila H, Toutain PL, Picard-Hagen N. Bisphenol S instead of Bisphenol A: Toxicokinetic investigations in the ovine materno-feto-placental unit. Environ Int 2018; 120:584-592. [PMID: 30212803 DOI: 10.1016/j.envint.2018.08.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Revised: 08/03/2018] [Accepted: 08/07/2018] [Indexed: 06/08/2023]
Abstract
Bisphenol S (BPS) is widely used as a substitute for Bisphenol A in consumer products. Despite its potential endocrine-disrupting effects and widespread exposure, toxicokinetic data, particularly during the critical period of pregnancy, are not available for BPS. The objectives of our study were to evaluate the mechanisms determining fetal exposure to BPS and to BPS glucuronide (BPSG) and to compare them with those prevailing for BPA. The disposition of BPS and BPSG was evaluated in the materno-fetal unit of the catheterized pregnant ewe model, following intravenous administrations of BPS and BPSG to mothers and their fetuses. In a second experiment, the rate of BPS accumulation in the fetal compartment was determined under steady-state conditions after repeated intravenous BPS administrations to the mother. In the maternal compartment, BPS was mainly metabolized into BPSG and totally eliminated in urine. Only 0.40% of the maternal dose was transferred to the fetus. However, once in the fetal compartment, 26% of the fetal dose was rapidly eliminated through placental transfer, while 46% of BPS was metabolized into BPSG which remained trapped in the fetal compartment. Thus, the elimination of BPSG from the fetal compartment required its back-conversion into bioactive BPS, leading to an 87% enhancement of the fetal BPS exposure. Our findings demonstrate that, despite the low materno-fetal placental transfer of BPS, this substitute for BPA is able to accumulate in the fetal compartment after repeated maternal exposure, leading to chronic fetal exposure to BPS in a range of concentrations similar to those of BPA.
Collapse
Affiliation(s)
- Flore C Grandin
- Toxalim, INRA (Institut National de la Recherche Agronomique), Université de Toulouse, ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), Toulouse, France.
| | | | - Véronique Gayrard
- Toxalim, INRA (Institut National de la Recherche Agronomique), Université de Toulouse, ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), Toulouse, France.
| | - Glenn Gauderat
- Toxalim, INRA (Institut National de la Recherche Agronomique), Université de Toulouse, ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), Toulouse, France
| | - Hanna Mila
- Toxalim, INRA (Institut National de la Recherche Agronomique), Université de Toulouse, ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), Toulouse, France.
| | | | - Nicole Picard-Hagen
- Toxalim, INRA (Institut National de la Recherche Agronomique), Université de Toulouse, ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), Toulouse, France.
| |
Collapse
|
6
|
Gauderat G, Picard-Hagen N, Toutain PL, Servien R, Viguié C, Puel S, Lacroix MZ, Corbel T, Bousquet-Melou A, Gayrard V. Prediction of human prenatal exposure to bisphenol A and bisphenol A glucuronide from an ovine semi-physiological toxicokinetic model. Sci Rep 2017; 7:15330. [PMID: 29127374 PMCID: PMC5681680 DOI: 10.1038/s41598-017-15646-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Accepted: 10/30/2017] [Indexed: 11/23/2022] Open
Abstract
Bisphenol A (BPA) risk assessment is hampered by the difficulty of determining the extent of internal exposure in the human fetus and uncertainties regarding BPA toxicokinetics (TK) in the maternal-fetal unit. A feto-maternal TK model describing BPA and BPA glucuronide (BPAG) disposition in sheep was humanized, using human TK data obtained after d6-BPA administration on a cookie, to predict BPA and BPAG kinetics in the human mother-fetus unit. Validation of the model predictions included the assessed dose proportionality of BPA and BPAG disposition and the similarity between the simulated and measured time courses of BPA and BPAG in fetal rhesus monkeys after BPA maternal dosing. The model predicted fluctuations in fetal BPA concentrations associated with typical maternal exposure to BPA through the diet, with similar trough (0.011 ng/L vs 0.014 ng/L) and lower peak BPA concentrations (0.023 ng/L vs 0.14 ng/L) in fetal than in maternal plasma. BPAG concentrations in fetal plasma were predicted to increase over time to reach a steady value (29 ng/L) reflecting the cumulative BPA dose received by the fetus. Model-predicted BPAG concentrations in fetal plasma are consistent with reported levels in human cord blood that may be considered as relevant markers of the BPA dose entering blood throughout fetal life.
Collapse
Affiliation(s)
- Glenn Gauderat
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France.,Agreenium's International Research School (EIR-A), Paris, France
| | - Nicole Picard-Hagen
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France
| | - Pierre-Louis Toutain
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France
| | - Rémi Servien
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France
| | - Catherine Viguié
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France
| | - Sylvie Puel
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France
| | - Marlène Z Lacroix
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France
| | - Tanguy Corbel
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France
| | - Alain Bousquet-Melou
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France
| | - Véronique Gayrard
- Toxalim, Université de Toulouse, INRA (Institut National de la Recherche Agronomique), INP (Institut National Polytechnique de Toulouse) -ENVT (Ecole Nationale Vétérinaire de Toulouse), Toulouse, France.
| |
Collapse
|
7
|
Guignard D, Gauderat G, Gayrard V, Lacroix MZ, Picard-Hagen N, Puel S, Toutain PL, Viguié C. Characterization of the contribution of buccal absorption to internal exposure to bisphenol A through the diet. Food Chem Toxicol 2016; 93:82-8. [DOI: 10.1016/j.fct.2016.04.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Revised: 03/21/2016] [Accepted: 04/08/2016] [Indexed: 10/22/2022]
|
8
|
Gauderat G, Picard-Hagen N, Toutain PL, Corbel T, Viguié C, Puel S, Lacroix MZ, Mindeguia P, Bousquet-Melou A, Gayrard V. Bisphenol A glucuronide deconjugation is a determining factor of fetal exposure to bisphenol A. Environ Int 2016; 86:52-59. [PMID: 26540084 DOI: 10.1016/j.envint.2015.10.006] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Revised: 10/07/2015] [Accepted: 10/11/2015] [Indexed: 06/05/2023]
Abstract
Previous studies in experimental animals have shown that maternal exposure to bisphenol A (BPA) during late pregnancy leads to high plasma concentrations of BPA glucuronide (BPAG) in fetus compared to mother due to the inability of BPAG to cross the placental barrier. A recent in vitro study has reported that BPAG can exert adipogenic effect underlining the need for characterization of the fetal disposition of BPAG. Experiments were conducted in chronically catheterized fetal sheep to determine the contribution of BPAG hydrolysis to BPA to the elimination of BPAG from the fetal compartment and its resulting effect on the overall fetal exposure to free BPA. Serial sampling of fetal arterial blood, amniotic fluid, maternal venous blood and urine was performed following separate single doses of BPA and BPAG administered intravenously to eight fetal/maternal pairs after cesarean section, and repeated BPAG doses given to two fetal sheep. On average 67% of the BPA entering the fetal circulation was rapidly eliminated through fetal to maternal clearance, with a very short half-life (20 min), while the remaining fraction (24%) was glucuronoconjugated. BPA conjugation-deconjugation cycling was responsible for a 43% increase of the overall fetal exposure to free BPA. A very specific pattern of fetal exposure to free BPA was observed due to its highly increased persistence with a hydrolysis-dependent plasma terminal free BPA half-life of several tens of hours. These findings suggest that although the high fetal to maternal clearance of free BPA protects the fetus from transient increases in free BPA plasma concentrations associated with maternal BPA intake, low but sustained basal free BPA concentrations are maintained in the fetus through BPA conjugation-deconjugation cycling. The potential health implications of these low but sustained basal concentrations of free BPA in fetal plasma should be addressed especially when considering time-dependent effects.
Collapse
Affiliation(s)
- Glenn Gauderat
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France; Agreenium's International Research School (EIR-A), Paris, France.
| | - Nicole Picard-Hagen
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France.
| | - Pierre-Louis Toutain
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France.
| | - Tanguy Corbel
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France.
| | - Catherine Viguié
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France.
| | - Sylvie Puel
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France.
| | - Marlène Z Lacroix
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France.
| | - Pierre Mindeguia
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France.
| | - Alain Bousquet-Melou
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France.
| | - Véronique Gayrard
- INRA (Institut National de la Recherche Agronomique), UMR1331 (Unité Mixe de Recherche 1331), Toxalim, Research Center in Food Toxicology, Toulouse F-31027, France; Université de Toulouse, INPT (Institut National Polytechnique de Toulouse), ENVT (Ecole Nationale Vétérinaire de Toulouse), EIP (Ecole d'Ingénieurs de Purpan), UPS (Université Paul Sabatier), F-31076 Toulouse, France.
| |
Collapse
|
9
|
Gayrard V, Gauderat G, Lacroix MZ, Viguié C, Bousquet-Melou A, Toutain PL, Picard-Hagen N. Comment on "In Vitro Effects of Bisphenol A β-D-Glucuronide (BPA-G) on Adipogenesis in Human and Murine Preadipocytes". Environ Health Perspect 2015; 123:A289. [PMID: 26623714 PMCID: PMC4671231 DOI: 10.1289/ehp.1510315] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|